Epidemiology and antifungal susceptibility patterns of invasive candidiasis: A single-center study


  • Amna Younas Chughtai Institute of Pathology, Lahore Pakistan
  • Irim Iftikhar Chughtai Institute of Pathology, Lahore Pakistan
  • Karam Rasool Chughtai Institute of Pathology, Lahore Pakistan




Background: Invasive candidiasis remains a leading cause of morbidity and mortality. Despite the availability of various antifungal treatments, global reports continue to highlight resistance, treatment ineffectiveness, and outbreaks. This study aimed to analyze the epidemiology of various Candida species isolated from invasive samples and assess their antifungal susceptibility profiles.

Material and Methods: The study identified and evaluated a total of 200 Candida isolates, recovered over a 6-month period from various clinical specimens. These were assessed against various antifungals according to recommendations.

Results: Among the samples, blood (79%) and pus (12%) were the most commonly encountered sources of Candida isolation. Candida isolates comprised 14.5% (30) C. albicans and 85.5% (170) non-albicans species. Non-albicans species included 15% (30) C. guilliermondii, 14.5% (29) C. lusitaniae, 11.5% (22) C. tropicalis, 2.3% (4) C. auris, and 8.5% (17) C. parapsilosis. Overall, the strains showed 74% and 91% sensitivity to Fluconazole and Voriconazole, respectively, and 100% sensitivity to Caspofungin and Amphotericin B, with the exception of C. lusitaniae.

Conclusion: The susceptibility profile of antifungals is evolving. This study demonstrated a low rate of resistance to four antifungals in invasive candidiasis in Pakistan. None of the isolates were resistant to more than one drug. Early and prompt treatment through the implementation of an antifungal stewardship program and strict infection control is crucial.

Keywords: Invasive candidiasis (IC), Antifungal susceptibility profile, Fluconazole, Candidemia


Bilgin MK, Talan L, Evren E, Altıntas ND. Retrospective evaluation of risk factors for invasive candida infections in a Medical Intensive Care Unit. Infect Dis Clin Microbiol. 2022; 4(1): 62-71. DOI: https://doi.org/10.36519/idcm.2022.56

Paiva J-A, Pereira JM, Tabah A, Mikstacki A, de Carvalho FB, Koulenti D, et al. Characteristics and risk factors for 28-day mortality of hospital-acquired fungemias in ICUS: Data from the EUROBACT study. Crit Care. 2016; 20(1): 53.

DOI: https://doi.org/10.1186/s13054-016-1229-1

Bassetti M, Giacobbe DR, Vena A, Trucchi C, Ansaldi F, Antonelli M, et al. Incidence and outcome of invasive candidiasis in Intensive Care Units (ICUS) in Europe: Results of the EUCANDICU project. Crit Care. 2019;23(1): 219.

DOI: https://doi.org/10.1186/s13054-019-2497-3

Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJGT, Bohlius J, et al. Morbidity and mortality of candidemia in Europe: An epidemiologic meta-analysis. Clinical Microbiology and Infection. 2019; 25(10): 1200–12.

DOI: https://doi.org/10.1016/j.cmi.2019.04.024

Flevari A, Theodorakopoulou M, Velegraki A, Armaganidis A, Dimopolus G. Treatment of invasive candidiasis in the elderly: A review. Clin Interv Aging. 2013; 1199-208. DOI: https://doi.org/10.2147/cia.s39120

Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in Intensive Care Unit Study. Crit Care Med. 2011; 39(4): 665–70. DOI: https://doi.org/10.1097/ccm.0b013e318206c1ca

Farooqi JQ, Jabeen K, Saeed N, Iqbal N, Malik B, Lockhart SR, Zafar A, Brandt ME, Hasan R. Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility. J Med Microbiol. 2013; 62(Pt 2): 259-68. DOI: https://doi.org/10.1099/jmm.0.048785-0

Bels DD, Maillart E, Van Bambeke F, Redant S, Honoré PM. Existing and emerging therapies for the treatment of invasive candidiasis and Candidemia. Expert Opin Emerg Drugs. 2022; 27(4): 405–16. DOI: https://doi.org/10.1080/14728214.2022.2142207

Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJGT, Bohlius J, et al. Morbidity and mortality of candidaemia in Europe: An epidemiologic meta-analysis. Clin Microbiol Infect. 2019; 25(10): 1200-12. DOI: https://doi.org/10.1016/j.cmi.2019.04.024

Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018; 4(1): 18026. DOI: https://doi.org/10.1038/nrdp.2018.26

Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe candida infections in nonneutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 2002; 28(12): 1708–17. DOI: https://doi.org/10.1007/s00134-002-1540-y

Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: Challenges and future directions. Intensive Care Med. 2020; 46(11): 2001–14. DOI: https://doi.org/10.1007/s00134-020-06240-x

Senn L, Eggimann P, Ksontini R, Pascual A, Demartines N, Bille J, et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med. 2009; 35(5): 903–8. DOI: https://doi.org/10.1007/s00134-009-1405-8

Ferreira D, Grenouillet F, Blasco G, Samain E, Hénon T, Dussaucy A, et al. Outcomes associated with routine systemic antifungal therapy in critically ill patients with candida colonization. Intensive Care Med. 2015; 41(6): 1077–88. DOI: https://doi.org/10.1097/ccm.0b013e318236f297

Rattani S, Farooqi J, Hussain AS, Jabeen K. Spectrum and antifungal resistance of Candidemia in neonates with early- and late-onset sepsis in Pakistan. Pediatric Infect Dis J. 2021; 40(9): 814–20. DOI: https://doi.org/10.1097/INF.0000000000003161

Bhat J, Charoo B, Ashraf Y, Qazi I. Systemic candida infection in preterm babies: Experience from a tertiary care hospital of North India. J Clin Neonatol. 2019; 8(3): 151. DOI: https://doi.org/10.4103/jcn.JCN_9_19

Clancy CJ, Nguyen MH. Finding the “missing 50%” of invasive candidiasis: How nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013; 56(9): 1284–92. DOI: https://doi.org/10.1093/cid/cit006

Clancy C, Nguyen MH. Non-culture diagnostics for invasive candidiasis: Promise and unintended consequences. J Fungi. 2018; 4(1): 27. DOI: https://doi.org/doi10.3390/jof4010027

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the Sentry Antifungal Surveillance Program: Results for Candida species from 1997–2016. Open Forum Infect Dis. 2019; 6(Supplement_1): S79-S94. DOI: https://doi.org/10.1093/ofid/ofy358

Mirhendi H, Charsizadeh A, Eshaghi H, Nikmanesh B, Arendrup MC. Species distribution and antifungal susceptibility profile of candida isolates from blood and other normally sterile foci from pediatric ICU patients in Tehran, Iran. Medl Mycol. 2020; 58(2): 201-6. DOI: https://doi.org/10.1093/mmy/myz047

Lockhart SR, Pham CD, Kuykendall RJ, Bolden CB, Cleveland AA. Candida lusitaniae MICs to the echinocandins are elevated but FKS-mediated resistance is rare. Diagn Microbiol Infect Dis. 2016; 84(1): 52-4. DOI: https://doi.org/10.1016/j.diagmicrobio.2015.08.012

Lyman M, Forsberg K, Reuben J, Dang T, Free R, Seagle EE, et al. Notes from the field: Transmission of Pan-resistant and echinocandin-resistant candida auris in health care facilities―Texas and the District of Columbia, January–April 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(29): 1022-3. DOI: https://doi.org/10.15585/mmwr.mm7029a2

Forsberg K, Lyman M, Chaturvedi S, Schneider EC, Fischer J, Baynham DF, et al. 155. public health action-based system for tracking and responding to U.S. candida drug resistance: AR Lab Network, 2016–2019. Open Forum Infect Dis. 2020; 7(Supplement_1): S206-7. DOI: https://doi.org/10.1093/ofid/ofaa439.465

Baalaaji AR M. Invasive candidiasis in children: Challenges remain. Indian J Crit Care Med. 2022; 26(6): 667–8.

DOI: https://doi.org/10.5005/jp-journals-10071-24250

Riera FO, Caeiro JP, Angiolini SC, Vigezzi C, Rodriguez E, Icely PA, et al. Invasive candidiasis: Update and current challenges in the management of this mycosis in South America. Antibiotics (Basel). 2022; 11(7): 877.

DOI: https://doi.org/10.3390/antibiotics11070877